These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16967348)

  • 1. [The influence of vascular risk factors and white matter hyperintensities on the degree of motor impairment in Parkinson's disease].
    Derejko M; Sławek J; Wieczorek D; Dubaniewicz M; Lass P
    Neurol Neurochir Pol; 2006; 40(4):276-83. PubMed ID: 16967348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease.
    Sławek J; Wieczorek D; Derejko M; Dubaniewicz M; Brockhuis B; Sitek E; Wilczewska L; Roszmann A; Lass P
    Neurol Neurochir Pol; 2008; 42(6):505-12. PubMed ID: 19235103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral white matter hyperintensity in Parkinson's disease: a major risk factor for mild cognitive impairment.
    Kandiah N; Mak E; Ng A; Huang S; Au WL; Sitoh YY; Tan LC
    Parkinsonism Relat Disord; 2013 Jul; 19(7):680-3. PubMed ID: 23623194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy.
    Tepedino MF; Diana F; Abate F; Avallone AR; Caterino M; Erro R; Pellecchia MT; Manara R; Barone P; Picillo M
    J Neurol; 2024 Oct; 271(10):6866-6875. PubMed ID: 39222284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors.
    Sławek J; Roszmann A; Robowski P; Dubaniewicz M; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Kurzawski M; Bandurski T; Białecka M
    Neurodegener Dis; 2013; 12(1):1-12. PubMed ID: 22831964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voiding dysfunction in patients with Parkinson's disease: impact of neurological impairment and clinical parameters.
    Sammour ZM; Gomes CM; Barbosa ER; Lopes RI; Sallem FS; Trigo-Rocha FE; Bruschini H; Srougi M
    Neurourol Urodyn; 2009; 28(6):510-5. PubMed ID: 19191278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of motor impairment and disability in Parkinson disease: a population-based study.
    Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
    Neurology; 2005 Nov; 65(9):1436-41. PubMed ID: 16275832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of leukoaraiosis and the clinical severity of vascular Parkinsonism.
    Chen YF; Tseng YL; Lan MY; Lai SL; Su CS; Liu JS; Chang YY
    J Neurol Sci; 2014 Nov; 346(1-2):255-9. PubMed ID: 25240444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Depression in patients with Parkinson's disease].
    Sławek J; Derejko M; Lass P
    Neurol Neurochir Pol; 2003; 37(2):351-64. PubMed ID: 14558483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson's disease.
    Ham JH; Lee JJ; Sunwoo MK; Hong JY; Sohn YH; Lee PH
    Parkinsonism Relat Disord; 2016 Mar; 24():95-9. PubMed ID: 26776568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of white matter hyperintensities on the clinical features of Parkinson's disease.
    Sohn YH; Kim JS
    Yonsei Med J; 1998 Feb; 39(1):50-5. PubMed ID: 9529985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of the UPDRS bradykinesia subscale: equivalence, reliability and validity.
    Buck PO; Wilson RE; Seeberger LC; Conner JB; Castelli-Haley J
    J Parkinsons Dis; 2011; 1(3):253-8. PubMed ID: 23939305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
    Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M
    Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses.
    Louis ED; Levy G; Côte LJ; Mejia H; Fahn S; Marder K
    Mov Disord; 2002 May; 17(3):513-7. PubMed ID: 12112199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual rating of white matter hyperintensities in Parkinson's disease.
    Beyer MK; Aarsland D; Greve OJ; Larsen JP
    Mov Disord; 2006 Feb; 21(2):223-9. PubMed ID: 16161159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study.
    Basile AM; Pantoni L; Pracucci G; Asplund K; Chabriat H; Erkinjuntti T; Fazekas F; Ferro JM; Hennerici M; O'Brien J; Scheltens P; Visser MC; Wahlund LO; Waldemar G; Wallin A; Inzitari D;
    Cerebrovasc Dis; 2006; 21(5-6):315-22. PubMed ID: 16490940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.
    Solla P; Cannas A; Ibba FC; Loi F; Corona M; Orofino G; Marrosu MG; Marrosu F
    J Neurol Sci; 2012 Dec; 323(1-2):33-9. PubMed ID: 22935408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.
    Dalaker TO; Larsen JP; Dwyer MG; Aarsland D; Beyer MK; Alves G; Bronnick K; Tysnes OB; Zivadinov R
    Neuroimage; 2009 Oct; 47(4):2083-9. PubMed ID: 19539037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain atrophy and white matter hyperintensities in early Parkinson's disease(a).
    Dalaker TO; Larsen JP; Bergsland N; Beyer MK; Alves G; Dwyer MG; Tysnes OB; Benedict RH; Kelemen A; Bronnick K; Zivadinov R
    Mov Disord; 2009 Nov; 24(15):2233-41. PubMed ID: 19768730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.